Mogamulizumab for Cutaneous T-Cell Lymphoma

Recruiting in Palo Alto (17 mi)

+20 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Kyowa Kirin, Inc.

No Placebo Group

Prior Safety Data

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?This trial is testing a medication called mogamulizumab in adults with certain types of skin cancer that have come back or not responded to other treatments. The medication helps the immune system find and destroy cancer cells. Mogamulizumab is approved for treating various types of skin cancer.

Eligibility Criteria

This trial is for adults with certain types of skin lymphoma (CTCL) who have tried at least one systemic therapy without success. It's not open to those who've had a specific cell transformation, previous mogamulizumab treatment, or an allogeneic transplant.

Inclusion Criteria

My cancer is at a late stage and I've had at least one treatment that didn't work.

My diagnosis of mycosis fungoides or Sézary syndrome is confirmed by tissue analysis.

Exclusion Criteria

I have been treated with mogamulizumab before.

I have had a transplant from a donor.

Current evidence of large cell transformation;

Participant Groups

The study tests the safety and effects of mogamulizumab given every four weeks after initial weekly doses in patients with relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), which are subtypes of CTCL.

1Treatment groups

Experimental Treatment

Group I: MogamulizumabExperimental Treatment1 Intervention

Mogamulizumab is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺 Approved in European Union as Poteligeo for: